Skip to Content
MoleculesMolecules
  • Review
  • Open Access

8 January 2023

Applications of Capillary Electrophoresis for the Determination of Cannabinoids in Different Matrices

,
,
and
1
Department of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, “Ovidius” University of Constanța, 900470 Constanța, Romania
2
Pharmaceutical and Therapeutic Chemistry Department, Faculty of Pharmacy, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Târgu Mures, Romania
3
Pharmaceutical Technology and Cosmetology Department, Faculty of Pharmacy, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Târgu Mures, Romania
4
Biochemistry and Chemistry of Environmental Factors Department, Faculty of Pharmacy, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Târgu Mures, Romania

Abstract

Cannabinoids, terpenophenolic chemicals found only in cannabis, are primarily responsible for cannabis pharmacologic effects; nearly 150 distinct cannabinoids have been identified thus far. Among these, the main psychoactive molecule, tetrahydrocannabinol (THC), and the non-psychoactive counterpart, cannabidiol (CBD) are distinguishable. In the past decade, a CBD-containing pharmaceutical preparation was approved by Food and Drug Administration (FDA) for the treatment of drug-resistant epileptic seizures in children, and research trials for a variety of additional medical conditions for which CBD has been suggested as a therapy are being conducted. Additionally, the number of “CBD-containing” dietary supplements, largely available online, is increasing rapidly. Consequently, the necessity for the development of qualitative and quantitative methodologies for the analysis of the bioactive components of Cannabis is rising because of the increase in the production of therapeutic cannabis products. One of the analytical methods with good potential in cannabinoids analysis is capillary electrophoresis (CE). It has advantages related to high separation efficiency, relatively short analysis time, and the small consumption of analytes and reagents which generates relatively lower operational costs than other methods. This review focuses on the use of CE techniques to examine biological matrices and plant materials for the presence of cannabinoids and other bioactive compounds found in cannabis. The advantages, drawbacks, and applicability of the various electromigration approaches are also assessed. The article provides an overview of the “state of the art” and the latest trends in CE-based methods for the determination of cannabinoids.

1. Introduction

The Cannabis sativa L. plant is annual herbaceous flowering plant species belonging to the Cannabaceae family, originally from Central Asia, which has been used for centuries to produce hemp fiber (used for clothing, rope, and paper), seeds (used as food) and as a medicinal plant [1]. Cannabis has been utilized since the dawn of human civilization for medicinal purposes and recreational use. Cannabis phenotypes are highly variable, and the plant is recognized to have three subspecies: Cannabis sativa subsp. Sativa, Cannabis sativa subsp. indica, and Cannabis sativa subsp. ruderalis [1,2].
Cannabis therapeutic ingredients are mainly concentrated in the female flowers of the plant; the so-called “resin” contains a wide range of terpenoids and cannabinoids. Cannabis’ medicinal properties are linked mainly to its cannabinoid content and terpenophenolic compounds which are found exclusively in cannabis. To date, almost 150 different cannabinoids have been identified [3]. Among these, we can identify the two major components in the cannabis plant: the main psychoactive compound, tetrahydrocannabinol (THC), and the non-psychoactive compound, cannabidiol (CBD) [3,4]
The term cannabinoid refers to both natural cannabinoids (endocannabinoids; phytocannabinoids) and synthetic cannabinoids that operate on cannabinoid receptors. Phytocannabinoids refer to a group of oxygenated aromatic hydrocarbon metabolites derived from the Cannabis plant that contain 21 carbon atoms. Currently, phytocannabinoids are conventionally classified into 11 chemical classes, each named after the “lead” compound: cannabichromene (CBC), cannabidiol (CBD), cannabielsoin (CBE), cannabigerol (CBG), cannabicyclol (CBL), cannabinol (CBN), cannabinodiol (CBND), cannabitriol (CBT), tetrahydrocannabinol (THC), (−)-Δ8-trans-tetrahydrocannabinol (Δ8-THC), and miscellaneous phytocannabinoids (Figure 1) [5]. The existing heterogeneity in phytocannabinoid concentration between and among different chemotypes has significant implications for medical cannabis formulations and administration [6].
Figure 1. The structure of the most common phytocannabinoids [5].
Thousands of Cannabis strains are currently available on the market with varying phytocannabinoid compositions, which are classified based on the total quantity of THC and CBD. Cannabis has gained substantial attention in recent years as an increasing number of countries legalize Cannabis for medicinal and recreational use. There is quite a high degree of variation in the amounts of THC allowed by various legislation in hemp preparations, ranging from 0.05 to 0.5%. The legal status of Cannabis’s main components varies from country to country, with some countries classifying THC and CBD in the same class of illegal narcotics and others legalizing CBD products [7,8].
While CBD is chemically related to THC (the difference is that CBD is a bicyclic while THC is a tricyclic compound, but the molecular mass is the same) (Figure 2), CBD has shown significant tolerance in humans with limited abuse potential. CBD’s good safety profile has resulted in the recent reduction of legal and regulatory restrictions, made CBD products available in numerous countries, and led to a surge in interest in CBD treatment [9]. This led to the situation that CBD therapeutic demand has outpaced scientific research and regulatory development, creating a complex ecosystem of disinformation and dubious health claims.
Figure 2. Chemical structures of CBD (2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol) and THC ((6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol).
Currently, there are two phytocannabinoid pharmaceutical preparations approved by the USA Food and Drug Administration (FDA): Epidiolex®—oral solution (contains only CBD) and Sativex®—oromucosal spray (contains both CBD and THC). Epidiolex® is a medication used to treat seizures in Lennox-Gastaut or Dravet syndrome in individuals aged 2 years and older [10,11]. Because of their popularity, various CBD-containing dietary supplements can be found on the market. Furthermore, CBD can be found in essential oils, personal care products, foods, and medicinal formulations.
CBD is a versatile substance in terms of the pathologies it can treat and for which it could be administered as adjuvant treatment, among these we can mention epilepsy, anxiety, neuropathic pain, or cancer [12].
Cannabinoids are lipophilic and can be rapidly absorbed; much of the available pharmacokinetic data focus on CBD and THC. CBD and THC pharmacokinetic profiles differ significantly between users, dosage and form, acute and chronic usage, and mode of administration. Smoking and vaporizing cannabis results in higher blood levels of cannabinoids, a faster start of the effect, and more bioavailability by comparison to oral ingestion [13].
Whereas THC is a partial agonist of the cannabinoid receptors (CB1 and CB2) in the endogenous cannabinoid system and exerts its psychoactive and pain modulatory effects via CB1 agonist action, CBD has relatively little affinity for the orthostatic sites of these receptors and may even inhibit THC binding at CB1 receptors via another mechanism. Cannabinoids have a wide range of effects via the activation of G-protein-coupled cannabinoid receptors in the brain and peripheral organs. CBD has also been demonstrated to bind to non-cannabinoid receptors [13,14].
Synthetic cannabinoids are a class of “designer drugs” that binds to the same receptors to which endocannabinoids attach. Synthetic cannabinoids are becoming a major public health problem due to their rising usage as well as their unpredictable toxicity and misuse potential. Synthetic cannabinoids are linked to greater rates of toxicity and hospitalization than natural cannabis, most likely because they are direct agonists of cannabinoid receptors, whereas THC is a partial agonist [15].
Due to the limited means of consumers to analyze the chemical composition of Cannabis products, people may unwittingly purchase items with low quality, especially in regard to dietary supplements acquired online [16]. As Cannabis product usage becomes more widely acknowledged, it becomes increasingly vital to evaluate the cannabinoid profile and quantity of cannabis products to assure consistency and quality of the products. Developing effective analytical methods for the determination of CBD and other related cannabinoids is a major issue in pharmaceutical and biological research because of its potential use as a medication or as a component of dietary supplements.
Several reviews regarding the analysis methods applied for the determination of cannabinoids from different matrices have been published in the last 15 years; among these, we can distinguish those by Presley [17], Raharjo and Verpoorte [18], Ramirez et al. [19], Pourseyed Lazarjani et al. [20] and Micalizzi et al. [21]. Most of the methods used for the determination of cannabinoids are chromatographic ones, especially high-performance liquid chromatography (HPLC) and gas chromatography (GC). For the analysis of CBD and related compounds, HPLC combined with diode-array (UV/DAD) or mass spectrometry (MS) detection is without a doubt the most widely used analytical technique. However, the tendency for the application of novel analytical approaches for the quantitation of CBD and related compounds in plant material and other derived products, such as nuclear magnetic resonance spectroscopy (NMR) and near-infrared spectroscopy (NIR), can be explained by the growing need for faster, more automated, and environmentally friendly methodologies [22,23].
Capillary electrophoresis (CE) techniques are considered an alternative and a complementary method for HPLC techniques, with advantages related to high separation efficiency, relatively short analysis time, and especially low consumption of analytes and reagents which generates lower operational cost. Additionally, because usually in CE low amounts of organic solvents are used, this technique folds very well on the concept of “green chemistry” [24].
Several CE applications for the determination of cannabinoids in different matrices have been published in the last 20 years, but to our knowledge, no review regarding the use of electromigration techniques in the analysis of cannabinoids has been published so far.
This review focuses on the CE-based analytical methods employed to analyze both plant materials and biological matrices concerning both cannabinoid content and other bioactive substances contained in cannabis. To provide helpful recommendations for the selection of the most appropriate electromigration method for the analysis of cannabinoids in either biological or plant samples, essential issues are discussed. The advantages, drawbacks, and applicability of the various electromigration approaches are also assessed.

3. Conclusions

The analytical scenario surrounding cannabinoids determination is extremely diverse comprising different analytical methods, as no standardization on the criteria for the determination of CBD, THC and related compounds in the plant, plant-derived products, and biological matrices has been established thus far. The identification and detection of a wide range of cannabinoids in various types of matrices has become a difficult challenge for analytical chemists. Taking into consideration these aspects, the purpose of this study is to provide an overview of the most recent achievements in the field of cannabinoids analysis and bioanalysis by CE.
Analyzing the number of published CE studies for the determination of cannabinoids, we conclude that are only a few, considering that the method has greater potential to be used in this area.
CE is an alternative separation technique for the more frequently used chromatographic ones (HPLC, GC) based on the intrinsic charges of the analytes and relies on their different electrophoretic mobilities to separate them inside a narrow silica capillary. The benefits of CE are widely established and are mostly related to the speed of analysis, separation efficiency, and the minimal consumption of analytes and reagents which will generate relatively smaller operational costs [43]. However, one must consider the CE detection limits, which are often several orders of magnitude larger than those of conventional chromatographic and spectroscopic methods. The discovery of techniques to boost CE sensitivity has therefore become a critical subject, with several approaches described. More adequate LOD can be obtained by using, if possible, fluorescence or MS detection instead of classic UV detection [44].
The lack of sensitivity has been addressed through a variety of methods, including the use of chromatographic and electrophoretic preconcentration techniques. These stages, however, have certain drawbacks, such as more sophisticated and time-consuming procedures and reduced reproducibility [45]. Future advancements in this area should center on the development and use of more complex and efficient on-line preconcentration procedures to obtain superior analytical performance.
Cannabinoids have very similar chemical structures, and consequently, similar charges and electrophoretic mobilities; therefore, separation by CZE is difficult to achieve, resulting in overlapping peaks, migration together with the EOF, or excessively long separation times.
Cannabinoids are hydrophobic substances, poorly soluble in water, requiring the presence of an organic solvent (acetonitrile, methanol) in the BGE to optimize solubility and separation. Taking into consideration these aspects, NACE could be an optimal solution for cannabinoids determination by CE. NACE involves the separation of analytes in a medium composed of organic solvents. Changes in separation selectivity in NACE contribute to better separation of certain chemicals with extremely modest charge-to-mass differences in aqueous phases [46].
Another approach exploiting the hydrophobic nature of cannabinoids is the use of MEKC with SDS as a surfactant, which is a suitable separation method for both neutral and ionized substances. MEKC is ideal for the separation of neutral chemicals, such as cannabinoids, and has a high capacity to cope with complicated biological and non-biological matrices. Employing stacking in SDS presence to suppress EOF can result in increased sensitivity, overcoming one of CE’s greatest problems [47]. However, the analysis of neutral substances by MEKC-MS has a significant disadvantage because commonly employed surfactants, such as SDS, are nonvolatile and can induce analyte signal suppression and spectrometer contamination. When connected to MS, a partial filling strategy of MEKC must be employed to minimize ion suppression owing to the presence of surfactants in the ESI and to reduce MS contamination. This problem can be also resolved using so-called “MS-friendly” surfactants like perfluorooctanoic acid [48].
An important issue is also the detection of synthetic cannabinoids; these substances are purposely added in herbal blends and have significant affinities for cannabinoid receptors; some synthetic cannabinoids are more potent than the main psychoactive ingredient in cannabis (THC). Therefore, the development of simple screening approaches is crucial to identify these cannabinoids. The hyphenation of CE with MS offers high sensitivity and the possibility of structurally characterizing analytes, like “spiced” synthetic cannabinoids.
Most of the available research focuses on identifying cannabinoids on biological samples, with urine being the most used matrix. Considering this, additional effort is required to create CE-based methods suitable for assessing additional biological fluids and other various matrix types.
Due to the hydrophobic nature of cannabinoids, CE techniques are not the first-choice methods for their determination, and in this case, LC-MS might be preferable to be used.
Relatively few of the reported publications offer thorough method validation in accordance with generally recognized worldwide regulations, which is a disadvantage because it has a detrimental influence on the methods’ reliability. The next challenge for researchers will be to design CE-based processes that allow method application with more sensitivity, accuracy, and reliability than is typically attained using chromatographic techniques.

Author Contributions

Conceptualization, N.M.B. and G.H.; methodology, N.M.B. and G.H.; investigation, N.M.B., G.H., R.A.V. and A.P.; writing—original draft preparation, N.M.B., G.H., R.A.V. and A.P.; writing—review and editing, N.M.B., G.H., R.A.V. and A.P.; supervision, N.M.B. and G.H.; project administration, G.H.; funding acquisition, G.H. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the University of Medicine, Pharmacy, Science and Technology “George Emil Palade” of Târgu Mureș, internal grant contract number 511/3/17.01.2022 (G.H., R.A.V.)

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Not applicable.

Abbreviations

BGE—background electrolyte; β-CD—β-cyclodextrin; CBC—cannabichromene; CBD—cannabidiol; CBE—cannabielsoin; CBG—cannabigerol; CBL—cannabicyclol; CBN—cannabinol; CBND—cannabinodiol; CBT—cannabitriol; CE—capillary electrophoresis; CEC—capillary electrochromatography; CMC—critical micellar concentration; CZE—capillary zone electrophoresis; DAD—diode array detection; ED—electrochemical detection; EOF—electro osmotic flow; ESI—electrospray ionization; FDA—Food and Drug Administration; GC—gas chromatography; HPLC—high performance liquid chromatography; LEDIF—light-emitting diode induced fluorescence; LLE—liquid-liquid extraction; LOD—limit of detection; MEKC—micellar electrokinetic chromatography; MRM—multiple reaction mode; MS—mass spectrometry; NACE—non-aqueous capillary electrophoresis; NIR—near infrared spectroscopy; NMR—nuclear magnetic resonance spectroscopy; RP—reverse phase; SDS—sodium dodecyl sulfate; SPE—solid-phase extraction; THC—tetrahydrocannabinol; Δ8-THC—(−)-Δ8-trans-tetrahydrocannabinol; THC-OH—11-hydroxy-Δ9-THC; THC-COOH—11-nor-9-carboxy-Δ8-THC.

References

  1. Klumpers, L.E.; Thacker, D.L. A brief background on cannabis: From plant to medical indications. J. AOAC Int. 2019, 102, 412–420. [Google Scholar] [CrossRef] [PubMed]
  2. Bonini, S.A.; Premoli, M.; Tambaro, S.; Kumar, A.; Maccarinelli, G.; Memo, M.; Mastinu, A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J. Ethnopharmacol. 2018, 227, 300–315. [Google Scholar] [CrossRef] [PubMed]
  3. Hazekamp, A.; Fischedick, J.T. Cannabis-from cultivar to chemovar. Drug Test. Anal. 2012, 4, 660–667. [Google Scholar] [CrossRef] [PubMed]
  4. Morales, P.; Reggio, P.H.; Jagerovic, N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front. Pharmacol. 2017, 8, 422. [Google Scholar] [CrossRef] [PubMed]
  5. Hanuš, L.O.; Meyer, S.M.; Muñoz, E.; Taglialatela-Scafati, O.; Appendino, G. Phytocannabinoids: A unified critical inventory. Nat. Prod. Rep. 2016, 33, 1357–1392. [Google Scholar] [CrossRef]
  6. Reekie, T.A.; Scott, M.P.; Kassiou, M. The evolving science of phytocannabinoids. Nat. Rev. Chem. 2017, 2, 1–12. [Google Scholar] [CrossRef]
  7. Carliner, H.; Brown, Q.L.; Sarvet, A.L.; Hasin, D.S. Cannabis use, attitudes, and legal status in the US: A review. Prev. Med. 2017, 104, 13–23. [Google Scholar] [CrossRef]
  8. Vlad, R.A.; Hancu, G.; Ciurba, A.; Antonoaea, P.; Rédai, E.M.; Todoran, N.; Silasi, O.; Muntean, D.L. Cannabidiol-therapeutic and legal aspects. Die Pharmazie 2020, 75, 463–469. [Google Scholar]
  9. Nelson, K.M.; Bisson, J.; Singh, G.; Graham, J.G.; Chen, S.N.; Friesen, J.B.; Dahlin, J.L.; Niemitz, M.; Walters, M.A.; Pauli, G.F. The essential medicinal chemistry of cannabidiol (CBD). J. Med. Chem. 2020, 63, 12137–12155. [Google Scholar] [CrossRef]
  10. Abu-Sawwa, R.; Scutt, B.; Park, Y. Emerging use of Epidiolex (cannabidiol) in epilepsy. J. Pediatr. Pharmacol. Ther. 2020, 25, 485–499. [Google Scholar] [CrossRef]
  11. Sastre-Garriga, J.; Vila, C.; Clissold, S.; Montalban, X. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Rev. Neurother. 2011, 11, 627–637. [Google Scholar] [CrossRef] [PubMed]
  12. White, C.M. A review of human studies assessing cannabidiol’s (CBD) therapeutic actions and potential. J. Clin. Pharmacol. 2019, 59, 923–934. [Google Scholar] [CrossRef] [PubMed]
  13. Lucas, C.J.; Galettis, P.; Schneider, J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 2018, 84, 2477–2482. [Google Scholar] [CrossRef]
  14. Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.M.; Denovan-Wright, E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. Br. J. Pharmacol. 2015, 172, 4790–4805. [Google Scholar] [CrossRef]
  15. Mills, B.; Yepes, A.; Nugent, K. Synthetic cannabinoids. Am. J. Med. Sci. 2015, 350, 59–62. [Google Scholar] [CrossRef]
  16. Fasinu, P.S.; Phillips, S.; ElSohly, M.A.; Walker, L.A. Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy 2016, 36, 781–796. [Google Scholar] [CrossRef] [PubMed]
  17. Presley, B.C.; Jansen-Varnum, S.A.; Logan, B.K. Analysis of synthetic cannabinoids in botanical material: A review of analytical methods and findings. Forensic Sci. Rev. 2013, 25, 27–46. [Google Scholar] [PubMed]
  18. Raharjo, T.J.; Verpoorte, R. Methods for the analysis of cannabinoids in biological materials: A review. Phytochem. Anal. 2004, 15, 79–94. [Google Scholar] [CrossRef]
  19. Ramirez, C.L.; Fanovich, M.A.; Churio, M.S. Cannabinoids: Extraction methods, analysis, and physicochemical characterization. Stud. Nat. Prod. Chem. 2019, 61, 143–173. [Google Scholar]
  20. Pourseyed Lazarjani, M.; Torres, S.; Hooker, T.; Fowlie, C.; Young, O.; Seyfoddin, A. Methods for quantification of cannabinoids: A narrative review. J. Cannabis Res. 2020, 2, 1–10. [Google Scholar] [CrossRef]
  21. Micalizzi, G.; Vento, F.; Alibrando, F.; Donnarumma, D.; Dugo, P.; Mondello, L. Cannabis Sativa L.: A comprehensive review on the analytical methodologies for cannabinoids and terpenes characterization. J. Chromat. A 2021, 1637, 461864. [Google Scholar] [CrossRef] [PubMed]
  22. Citti, C.; Braghiroli, D.; Vandelli, M.A.; Cannazza, G. Pharmaceutical and biomedical analysis of cannabinoids: A critical review. J. Pharm. Biomed. Anal. 2018, 147, 565–579. [Google Scholar] [CrossRef] [PubMed]
  23. Brighenti, V.; Protti, M.; Anceschi, L.; Zanardi, C.; Mercolini, L.; Pellati, F. Emerging challenges in the extraction, analysis and bioanalysis of cannabidiol and related compounds. J. Pharm. Biomed. Anal. 2021, 192, 113633. [Google Scholar] [CrossRef] [PubMed]
  24. Řemínek, R.; Foret, F. Capillary electrophoretic methods for quality control analyses of pharmaceuticals: A review. Electrophoresis 2021, 42, 19–37. [Google Scholar] [CrossRef] [PubMed]
  25. Kenndler, E. A critical overview of non-aqueous capillary electrophoresis. Part I: Mobility and separation selectivity. J. Chromat. A 2014, 1335, 16–30. [Google Scholar] [CrossRef]
  26. Kenndler, E. A critical overview of non-aqueous capillary electrophoresis. Part II: Separation efficiency and analysis time. J. Chromat. A 2014, 1335, 31–41. [Google Scholar] [CrossRef]
  27. Backofen, U.; Matysik, F.M.; Lunte, C.E. Determination of cannabinoids in hair using high-pH non-aqueous electrolytes and electrochemical detection: Some aspects of sensitivity and selectivity. J. Chromat. A 2002, 942, 259–269. [Google Scholar] [CrossRef]
  28. Iwamuro, Y.; Iio-Ishimaru, R.; Chinaka, S.; Takayama, N.; Hayakawa, K. Analysis of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid and its glucuronide in urine by capillary electrophoresis/mass spectrometry. Biomed. Chromat. 2012, 26, 1452–1456. [Google Scholar] [CrossRef]
  29. Mazina, J.; Spiljova, A.; Vaher, M.; Kaljurand, M.; Kulp, M. A rapid capillary electrophoresis method with LED-induced native fluorescence detection for the analysis of cannabinoids in oral fluid. Anal. Methods 2015, 7, 7741–7747. [Google Scholar] [CrossRef]
  30. Saar-Reismaa, P.; Erme, E.; Vaher, M.; Kulp, M.; Kaljurand, M.; Mazina-Sinkar, J. In situ determination of illegal drugs in oral fluid by portable capillary electrophoresis with deep UV excited fluorescence detection. Anal. Chem. 2018, 90, 6253–6258. [Google Scholar] [CrossRef]
  31. Zaripov, E.A.; Lee, T.; Dou, Y.; Harris, C.S.; Egorov, A.; Berezovski, M.V. Single-run separation and quantification of 14 cannabinoids using capillary electrophoresis. Separations 2021, 8, 30. [Google Scholar] [CrossRef]
  32. Hiroyuki, N.; Terabe, S. Micellar electrokinetic chromatography perspectives in drug analysis. J. Chromat. A 2006, 735, 3–27. [Google Scholar] [CrossRef]
  33. Silva, M. Micellar electrokinetic chromatography: A review of methodological and instrumental innovations focusing on practical aspects. Electrophoresis 2013, 34, 141–158. [Google Scholar] [CrossRef] [PubMed]
  34. Weinberger, R.; Lurie, I.S. Micellar electrokinetic capillary chromatography of illicit drug substances. Anal. Chem. 1991, 63, 823–827. [Google Scholar] [CrossRef]
  35. Wernly, P.; Thormann, W. Confirmation testing of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in urine with micellar electrokinetic capillary chromatography. J. Chromat. A 1992, 608, 251–256. [Google Scholar] [CrossRef]
  36. Su, H.L.; Feng, L.I.; Jen, H.P.; Hsieh, Y.Z. Using sweeping micellar electrokinetic chromatography to analyze Δ9-tetrahydrocannabinol and its major metabolites. J. Chromat. A 2009, 1216, 3512–3517. [Google Scholar] [CrossRef] [PubMed]
  37. Gottardo, R.; Bertaso, A.; Pascali, J.; Sorio, D.; Musile, G.; Trapani, E.; Seri, C.; Sepelloni, G.; Tagliaro, F. Micellar electrokinetic chromatography: A new simple tool for the analysis of synthetic cannabinoids in herbal blends and for the rapid estimation of their log P values. J. Chromat. A 2012, 1267, 198–205. [Google Scholar] [CrossRef]
  38. Akamatsu, S.; Mitsuhashi, T. MEKC–MS/MS method using a volatile surfactant for the simultaneous determination of 12 synthetic cannabinoids. J. Sep. Sci. 2014, 37, 304–307. [Google Scholar] [CrossRef] [PubMed]
  39. Cheng, H.L.; Tsai, Y.H.; Hsu, W.L.; Lin, Y.H. An on-line stacking capillary electrophoresis method for the analysis of Δ9-tetrahydrocannabinol and its metabolites. J. Chromat. A 2015, 1426, 226–232. [Google Scholar] [CrossRef]
  40. Švidrnoch, M.; Přibylka, A.; Maier, V. Determination of selected synthetic cannabinoids and their metabolites by micellar electrokinetic chromatography–mass spectrometry employing perfluoroheptanoic acid-based micellar phase. Talanta 2016, 150, 568–576. [Google Scholar] [CrossRef] [PubMed]
  41. Bartle, K.D.; Myers, P. Theory of capillary electrochromatography. J. Chromat. A 2001, 916, 3–23. [Google Scholar] [CrossRef]
  42. Lurie, I.S.; Meyers, R.P.; Conver, T.S. Capillary electrochromatography of cannabinoids. Anal. Chem. 1998, 70, 3255–3260. [Google Scholar] [CrossRef]
  43. Toraño, J.S.; Ramautar, R.; de Jong, G. Advances in capillary electrophoresis for the life sciences. J. Chromat. B 2019, 1118, 116–136. [Google Scholar] [CrossRef] [PubMed]
  44. Kristoff, C.J.; Bwanali, L.; Veltri, L.M.; Gautam, G.P.; Rutto, P.K.; Newton, E.O.; Holland, L.A. Challenging bioanalyses with capillary electrophoresis. Anal. Chem. 2019, 92, 49–66. [Google Scholar] [CrossRef] [PubMed]
  45. Simpson Jr, S.L.; Quirino, J.P.; Terabe, S. On-line sample preconcentration in capillary electrophoresis: Fundamentals and applications. J. Chromat. A 2008, 1184, 504–541. [Google Scholar] [CrossRef] [PubMed]
  46. Riekkola, M.L.; Jussila, M.; Porras, S.P.; Valkó, I.E. Non-aqueous capillary electrophoresis. J. Chromat. A 2000, 892, 155–170. [Google Scholar] [CrossRef]
  47. Quirino, J.P.; Terabe, S. Stacking of neutral analytes in micellar electrokinetic chromatography. J. Capill. Electrophor. 1997, 4, 233–245. [Google Scholar]
  48. Yang, L.; Lee, C.S. Micellar electrokinetic chromatography-mass spectrometry. J. Chromat. A 1997, 780, 207–218. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.